S1. Checklist. TRIPOD Checklist

Section/Topic	1	Checklist Item	Page
Title and abstract			
Title	1	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	Title Page
Abstract	2	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	Abstract
Introduction			
Background and objectives	3a	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Introduction, paragraphs 1-3
	3b	Specify the objectives, including whether the study describes the development or validation of the model or both.	Introduction, paragraph 4
Methods			
Source of data	4a	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	Methods, data source and participants
	4b	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	Methods, data source and participants
Participants	5a	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	Methods, data source and participants
Participants	5b	Describe eligibility criteria for participants.	Methods, data source and participants
	5c	Give details of treatments received, if relevant.	N/A
Outcome	6a	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	Methods, data source and participants
	6b	Report any actions to blind assessment of the outcome to be predicted	Methods, data source and participants
Predictors	7a	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	Methods, VACO Index components
	7b	Report any actions to blind assessment of predictors for the outcome and other predictors.	Methods, statistical analysis
Sample size	8	Explain how the study size was arrived at.	Methods, data source and participants
Missing data	9	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	Methods, statistical analysis
	10c	For validation, describe how the predictions were calculated.	Methods, statistical analysis
Statistical analysis methods	10d	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	Methods, statistical analysis
	10e	Describe any model updating (e.g., recalibration) arising from the validation, if done.	Methods, statistical analysis
Risk groups	11	Provide details on how risk groups were created, if done.	Methods, statistical analysis
Development vs. validation	12	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	Methods, data source and participants
Results			
Participants	13a	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	Results, participants

	13b	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	Results, participants
	13c	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	Results, participants
Model performance	16	Report performance measures (with CIs) for the prediction model.	Results, risk factors
Model-updating	17	If done, report the results from any model updating (i.e., model specification, model performance).	Results, VACO Index supplemented
Discussion			· · ·
Limitations	18	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	Discussion, limitations
	19a	For validation, discuss the results with reference to performance in the development data, and any other validation data.	Discussion, paragraphs 1-2
Interpretation	19b	Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.	Discussion, paragraphs 1-5
Implications	20	Discuss the potential clinical use of the model and implications for future research.	Discussion, paragraph 3
Other information			
Supplementary information	21	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	Discussion, paragraph 3
Funding	22	Give the source of funding and the role of the funders for the present study.	Funding

Comorbidity	ICD-10 Diagnosis Codes	Weight
AIDS (acquired immunodeficiency	B20.x–B22.x, B24.x	6
syndrome)		
Cancer	C00.x-C26.x, C30.x-C34.x, C37.x-C41.x,	2
	C43.x, C45.x–C58.x, C60.x–C76.x, C81.x–	
	C85.x, C88.x, C90.x–C97.x	
Cancer, metastatic	C77.x–C80.x	6
Cerebrovascular disease	G45.x, G46.x, H34.0, I60.x–I69.x	1
Chronic pulmonary disease	I27.8, I27.9, J40.x–J47.x, J60.x–J67.x, J68.4,	1
	J70.1, J70.3	
Congestive heart failure (CHF)	109.9, 111.0, 113.0, 113.2, 125.5, 142.0, 142.5–	1
	I42.9, I43.x, I50.x, P29.0	
Dementia	F00.x-F03.x, F05.1, G30.x, G31.1	1
Diabetes	E10.0, E10.1, E10.6, E10.8, E10.9, E11.0,	1
	E11.1, E11.6, E11.8, E11.9, E12.0, E12.1,	
	E12.6, E12.8, E12.9, E13.0, E13.1, E13.6,	
	E13.8, E13.9, E14.0, E14.1, E14.6, E14.8,	
	E14.9	
Diabetes with complications	E10.2–E10.5, E10.7, E11.2–E11.5, E11.7,	2
	E12.2–E12.5, E12.7, E13.2–E13.5, E13.7,	
	E14.2–E14.5, E14.7	
Liver disease, mild	B18.x, K70.0–K70.3, K70.9, K71.3–K71.5,	1
	K71.7, K73.x, K74.x, K76.0, K76.2–K76.4,	
	K76.8, K76.9, Z94.4	
Liver disease, moderate or severe	I85.0, I85.9, I86.4, I98.2, K70.4, K71.1, K72.1,	3
	K72.9, K76.5, K76.6, K76.7	
Myocardial infarction (MI)	I21.x, I22.x, I25.2, I09.9, I11.0, I13.0, I13.2,	1
	I25.5, I42.0, I42.5–I42.9, I43.x, I50.x, P29.0	
Peptic ulcer disease (PUD)	K25.x–K28.x	1
Peripheral vascular disease (PVD)	I70.x, I71.x, I73.1, I73.8, I73.9, I77.1, I79.0,	1
	179.2, K55.1, K55.8, K55.9, Z95.8, Z95.9	
Plegia	G04.1, G11.4, G80.1, G80.2, G81.x, G82.x,	2
	G83.0–G83.4, G83.9	
Renal disease	I12.0, I13.1, N03.2–N03.7, N05.2–N05.7,	2
	N18.x, N19.x, N25.0, Z49.0–Z49.2, Z94.0,	
	Z99.2	
Rheumatic disease	M05.x, M06.x, M31.5, M32.x–M34.x, M35.1,	1
	M35.3, M36.0	

S1. Table: Charlson Comorbidity Index Determination from ICD-10 Diagnosis Codes

Index calculated by summing comorbidity weights. Three comorbidity pairs are mutually exclusive: Cancer or Cancer, metastatic; Diabetes or Diabetes with complications; and Liver disease, mild or Liver disease, moderate or severe – only use the higher weight, not both.

Adapted from Quan *et al.*, Coding algorithms for defining comorbidities in ICD-9 and ICD-10 administrative data. *Med Care* 2005; 43(11): 1130-1139.

Variable	Coefficient	<u>Z</u>	P-value	OR	<u>95% CI</u>
Age, years					
20-49	-2.228678713	-2.83	0.005	0.11	0.02 - 0.50
50-54	0.0		-	1.00	-
55-59	0.400599289	0.97	0.334	1.49	0.66 - 3.36
60-64	0.941322019	2.50	0.013	2.56	1.22 - 5.37
65-69	1.295007128	3.49	< 0.001	3.65	1.77 - 7.55
70-74	1.629533438	4.55	< 0.001	5.10	2.53 - 10.3
75-79	1.763345763	4.72	< 0.001	5.83	2.81 - 12.12
80-89	1.927443543	4.96	< 0.001	6.87	3.21 - 14.72
≥90	2.018752269	4.39	< 0.001	7.53	3.06 - 18.54
Sex					
Female	0.0	-	-	1.00	-
Male	0.322291449	0.88	0.377	1.38	0.68 - 2.82
CCI and Age Interaction					
Term					
Age <85					
CCI					
0	0.0	-	-	-	-
1-3	0.612122574	2.76	0.006	1.84	1.19 - 2.85
4-5	0.825072847	3.36	0.001	2.28	1.41 - 3.69
6-9	0.956099733	3.84	< 0.001	2.60	1.60 - 4.24
≥10	1.395164653	4.25	< 0.001	4.04	2.12 - 7.68
Age 85+, any CCI	1.529325519	4.79	< 0.001	4.62	2.47 - 8.63
MI or PVD					
No	0.0	-	-	1.00	-
Yes	0.267265312	2.18	0.029	1.31	1.03 - 1.66
Constant	-4.216058062	-8.41	< 0.001	0.01	0.01 - 0.04

S1. File:	VACO	Index	Calculation	of Predicted	COVID-1	9 30-day	Mortality
-----------	------	-------	-------------	--------------	---------	----------	-----------

Abbreviations: OR = odds ratio; CI = confidence interval; CCI =Charlson comorbidity index; MI = myocardial infarction; PVD = peripheral vascular disease

 $\begin{array}{l} Calculation \ of \ predicted \ mortality \ risk: \\ coefficient_{sum} = Age_{coefficient} + Sex_{coefficient} + CCI_Age_{coefficient} + MI_PVD_{coefficient} + Constant_{coefficient} \\ OR_{calc} = exp(coefficient_{sum}) \\ risk_{pred} = OR_{calc} / (1 + OR_{calc}) \end{array}$

Example: 77 year old male with CCI = 5, but no history of MI or PVD coefficient_{sum} = 1.763345763 + 0.322291449 + 0.825072847 + 0.0 + (-4.216058062) = -1.305348004OR_{calc} = exp(-1.305348004) = 0. 271078182 risk_{pred} = 0.271078182 / (1 + 0.271078182) = 0.213266333 = 21%